Home › Multiple Myeloma › NCT05909059
CAR T-cell Therapy in Patients With Renal Dysfunction
RecruitingPhase 2
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma * Adequate bone marrow function to receive lymphodepleting chemotherapy * Renal function \</= 60mL/min/1.73m2 * ECOG 0-2 Exclusion Criteria: * Relative CNS disorders * Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator * Use of therapeutic dose systemic corticosteroids (defined as \>20mg/day prednisone or equivalent) within 72 hours of CAR-T administration
About the study
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
What is being tested
- Fludarabine (drug)
- Cyclophosphamide (drug)
Sponsor: Northside Hospital, Inc. · Participants: 20 · Started: Nov 18, 2024
Contact the study team
- Melhem Solh, MD · Phone: 404-255-1930
- Caitlin Guzowski, MBA, MHA · Phone: 404-851-8523
Official record on ClinicalTrials.gov — NCT05909059
Locations in the U.S.
| Georgia | Caitlin Guzowski, Atlanta |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.